Hidradenitis Suppurativa Treatment Market Size in the 7MM is expected to increase a significant CAGR by 2034, estimates DelveInsight | AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Biopharma SRL, MoonLake Immunotherapeutics, ACELYRIN I

DelveInsight's " Hidradenitis Suppurativa Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of hidradenitis suppurativa, historical and forecasted epidemiology as well as the hidradenitis suppurativa therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Hidradenitis Suppurativa Market Share @ Hidradenitis Suppurativa Market Outlook- https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Hidradenitis Suppurativa Market Report
• In March 2025, Novartis Pharmaceuticals announced a study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
• In March 2025, UCB Biopharma SRL conducted a study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS).
• In 2023, the total Hidradenitis Suppurativa Prevalence Cases in the 7MM were nearly 6.2 million. These cases are anticipated to increase by 2034.
• In the 7MM, the US accounted for the highest number of Hidradenitis Suppurativa Diagnosed Prevalent Cases with nearly 877,600 in 2023.
• Among EU4 and the UK, Germany accounted for the highest number of Hidradenitis Suppurativa Diagnosed Prevalent Cases whereas Spain occupied the bottom of the ladder.
• In the US, EU4 and the UK, hidradenitis suppurativa was seen to be slightly more common in females (~75%) than males (~25%). Conversely, in Japan, males represent nearly 70% of the total cases, while females account for around 30%.
• The age-specific data revealed that hidradenitis suppurativa was most prevalent in the age group of 30-39 years, which was nearly 26% of the total diagnosed cases of hidradenitis suppurativa in the US.
• Among all, Hurley Stage I was observed to be most prevalent, with approximately 480,000 cases in 2023 in the US.
• The leading Hidradenitis Suppurativa Companies such as AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Biopharma SRL, MoonLake Immunotherapeutics, ACELYRIN Inc., Novartis, Phoenicis Therapeutics, Eli Lilly and Company, Beth Israel Deaconess Medical Center, Novartis, Sanofi, Boehringer Ingelheim, Incyte Corporation, and others
• Promising Hidradenitis Suppurativa Therapies such as HUMIRA, COSENTYX (secukinumab), BIMZELX (bimekizumab), Eltrekibart (LY3041658), ROCEPHIN, Bimekizumab, Sonelokimab, Izokibep, CFZ533, PTM-001, Eltrekibart, Upadacitinib, Deucravacitinib, secukinumab, SAR442970, Spesolimab, SAR444656, Lutikizumab, Povorcitinib, and others

Stay ahead in the Hidradenitis Suppurativa Therapeutics Market with DelveInsight's Strategic Report @ Hidradenitis Suppurativa Market Outlook- https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hidradenitis Suppurativa Epidemiology Segmentation in the 7MM
• Total Hidradenitis Suppurativa Prevalent Cases
• Total Hidradenitis Suppurativa Diagnosed Prevalent Cases
• Hidradenitis Suppurativa Gender-Specific Prevalent Cases
• Hidradenitis Suppurativa Age-specific Prevalent Cases
• Hidradenitis Suppurativa Stage-specific Prevalence cases
• Hidradenitis Suppurativa Treated Prevalent Cases

Download the report to understand which factors are driving Hidradenitis Suppurativa Epidemiology trends @ Hidradenitis Suppurativa Prevalence- https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hidradenitis Suppurativa Marketed Drugs

• HUMIRA (adalimumab): AbbVie/Eisai
HUMIRA (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). In September 2015, the US FDA approved HUMIRA for the treatment of moderate-to-severe hidradenitis suppurativa in adults, and later in October 2018, for patients =12 years of age as well. The recommended dose of HUMIRA for adult patients with hidradenitis suppurativa is an initial dose of 160 mg (given in 1 day or split over 2 consecutive days), followed by 80 mg 2 weeks later. In Europe and Japan, HUMIRA biosimilars were launched in 2018 and 2021.

BIMZELX (Bimekizumab): UCB Biopharma
Bimekizumab is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. In April 2024, UCB announced that the European Commission granted marketing authorization for BIMZELX for the treatment of active moderate-to-severe hidradenitis suppurativa in adults with an inadequate response to conventional systemic hidradenitis suppurativa therapy. The approval follows a positive opinion issued in March 2024 by the Committee for Medicinal Products for Human Use of the EMA. In addition, in April 2024, the US FDA accepted for review the sBLA for BIMZELX for the treatment of adults with moderate-to-severe hidradenitis suppurativa. The drug has also been filed with PMDA in Japan for treating hidradenitis suppurativa.

Hidradenitis Suppurativa Emerging Drugs
• Povorcitinib (INCB054707): Incyte Corporation
Povorcitinib, developed by Incyte Corporation, is a selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules to treat patients with moderate-to-severe hidradenitis suppurativa. This therapeutic molecule is administered orally. Currently, the company is investigating this molecule in three different Phase III clinical trials (STOP-HS studies) for moderate-to-severe hidradenitis suppurativa. The company expects the Phase III STOP-HS trial data in 2025. In addition, the company also anticipates the potential launch of povorcitinib for hidradenitis suppurativa by 2026-2027.

• Sonelokimab (M1095): MoonLake Immunotherapeutics
Sonelokimab (M1095) is an investigational ~40 kDa humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. Nanobodies represent a new generation of antibody-derived targeted therapies. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers.

To learn more about Hidradenitis Suppurativa treatment guidelines, visit @ Hidradenitis Suppurativa Treatment Market Landscape- https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hidradenitis Suppurativa Drugs Market Insight
Hidradenitis suppurativa is treated using a variety of therapeutic classes tailored to its severity. Topical treatments, including antibiotics and antiseptics, are often used for milder cases. Systemic therapies, such as oral antibiotics, hormonal treatments, and retinoids, are utilized for more extensive disease. Biologic therapies, particularly TNF-alpha inhibitors and interleukin inhibitors, are effective for moderate-to-severe hidradenitis suppurativa. Immunosuppressants like cyclosporine and methotrexate are also options. The diverse Hidradenitis Suppurativa pipeline includes treatments targeting interleukins (such as IL-17, IL-36, and IL-1a/b), PDE4 inhibitors, JAK inhibitors, and CXCR1 and CXCR2 inhibitors.

Hidradenitis Suppurativa Market Outlook
As there is no cure for hidradenitis suppurativa, early diagnosis, and treatment help prevent the disease from getting worse and forming additional scars, and the current treatment approaches depend on the severity and clinical staging of the disease. Regarding pharmacological treatment market options, the following therapies are available: topical and systemic antibiotics, corticosteroids, hormonal therapy, systemic retinoids, zinc supplements, and immunosuppressive agents, including biologics. The mainstay of medical treatment of mild disease involves antibacterial washes and topical antibiotics. Acute flares may be managed by intralesional corticosteroids and/or minor surgical procedures. Oral therapies for mild-to-moderate hidradenitis suppurativa include extended courses of broad-spectrum antibiotics and systemic retinoids. In off-label therapies, the commonly used antibiotics are clindamycin, rifampicin, and tetracycline, as these antibiotics have shown their efficacy in the studies.

Learn more about the FDA-approved drugs for Hidradenitis Suppurativa @ Drugs for Hidradenitis Suppurativa Treatment- https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hidradenitis Suppurativa Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Hidradenitis Suppurativa Companies- AbbVie, Novartis, UCB Biopharma, Eli Lilly, Institut Pasteur, UCB Biopharma SRL, MoonLake Immunotherapeutics, ACELYRIN Inc., Novartis, Phoenicis Therapeutics, Eli Lilly and Company, Beth Israel Deaconess Medical Center, Novartis, Sanofi, Boehringer Ingelheim, Incyte Corporation, and others.
• Hidradenitis Suppurativa Therapies- HUMIRA, COSENTYX (secukinumab), BIMZELX (bimekizumab), Eltrekibart (LY3041658), ROCEPHIN, Bimekizumab, Sonelokimab, Izokibep, CFZ533, PTM-001, Eltrekibart, Upadacitinib, Deucravacitinib, secukinumab, SAR442970, Spesolimab, SAR444656, Lutikizumab, Povorcitinib, and others.
• Hidradenitis Suppurativa Therapeutic Assessment: Hidradenitis Suppurativa Current marketed and Hidradenitis Suppurativa emerging therapies
• Hidradenitis Suppurativa Market Dynamics: Hidradenitis Suppurativa Market drivers and Hidradenitis Suppurativa market barriers
• Hidradenitis Suppurativa Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hidradenitis Suppurativa Unmet Needs, KOL's views, Analyst's views, Hidradenitis Suppurativa Market Access and Reimbursement

Discover more about Hidradenitis Suppurativa Drugs in development @ Hidradenitis Suppurativa Clinical Trials Assessment- https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Hidradenitis Suppurativa Report Introduction
3. Hidradenitis Suppurativa Market Overview at a Glance: 7MM
4. Executive Summary of Hidradenitis Suppurativa
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Overview: Hidradenitis Suppurativa
8. Hidradenitis Suppurativa Treatment and Guidelines
9. Hidradenitis Suppurativa Epidemiology and Patient Population
10. Patient Journey of Hidradenitis Suppurativa
11. Key Endpoints in Hidradenitis Suppurativa Clinical Trials
12. Hidradenitis Suppurativa Marketed Drugs
13. Emerging Hidradenitis Suppurativa Drugs
14. Hidradenitis Suppurativa: Market Analysis
15. Market Access and Reimbursement
16. Hidradenitis Suppurativa Unmet Needs
17. Hidradenitis Suppurativa SWOT Analysis
18. Hidradenitis Suppurativa KOL Views
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.